Business Context and Reporting Period
This Form 8-K filing by Aquestive Therapeutics, Inc. (AQST) is dated August 23, 2022. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on stock price compliance.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5450(a)(1). Previously, on July 14, 2022, the company received notice of noncompliance because its common stock's minimum bid price fell below $1.00 per share for 30 consecutive business days. As of August 23, 2022, the company regained compliance after the minimum bid price met or exceeded $1.00 per share for ten consecutive business days.
Outlook, Risks, and Management Commentary
Management commentary is limited to the notification of regained compliance. The filing notes that the prior noncompliance notice had no immediate effect on trading and that the company had a 180-day grace period (until January 10, 2023) to regain compliance, which it successfully achieved early. No specific risks, contingencies, or unusual items beyond the listing status are detailed in this document.
Investor Verification Checklist
- Verify the current trading price of AQST common stock to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the company's continued listing status on The Nasdaq Global Market.
- Review subsequent filings for any recurrence of minimum bid price noncompliance.
- Check the company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial statements.